more_reports

The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports

US$200M Deal Accelerates Phase 3 Gene Therapy for Parkinsons

  ()
MeiraGTx Holdings Plc.'s (MGTX:NASDAQ) partnership with Hologen AI secures US$200 million to advance its Phase 3 gene therapy for Parkinson's. With regulatory milestones ahead, here's what's next.
Tags: Biotechnology / Pharmaceuticals

Biotech Stock Looks Like Is Has a Great Set Up

Contributed Opinion
  ()
Technical Analyst Clive Maund explains why he thinks Hemostemix Inc. (HEM:TSXV; HMTXF:OTCQB; 2VF0:FSE) is an Immediate Strong Buy.
Tags: Biotechnology / Pharmaceuticals

Utah Biotech's Treatment Demonstrates Significant Survival Advantage for ALS Patients

Research Report
  ()
Utah biotech Clene Inc. (CLNN:NASDAQ) recently shared new data, reporting the survival benefit of its CNM-Au8 treatment for ALS patients, according to a D. Boral Capital research note.
Tags: Biotechnology / Pharmaceuticals

Biotech Advancing Pivotal Phase III Breast Cancer Trial

Research Report
  ()
Oncolytics Biotech Inc. (ONCY:NASDAQ; ONC:TSX) recently updated its timelines for the company's clinical testing, regulatory review, and potential commercial launch of its oncolytic reovirus formulation pelareorep in breast cancer, according to a report from Leede Financial Inc.
Tags: Biotechnology / Pharmaceuticals

With Competitor Out, New Drug Gains Edge in Chronic Cough

Research Report
  ()
Phase 2b data, expected in H1/25, could support advancement of the therapeutic into late-stage development, noted a D. Boral Capital report.
Tags: Biotechnology / Pharmaceuticals

New Drug for Major Depressive Disorder Gets Good Surprise

Research Report
  ()
When a key competitor drops out, this treatment moves to top runner position; the biopharma behind it offers 1,084% upside, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Canadian Healthcare Co. Showcases Stable FQ424

Research Report
  ()
Leede Financial Inc. raised its target price on CareRX Corp. (CRRX:TSX; CHHHF:OTCMKTS). Read on to see why one Leede analyst rates the stock as a Buy.
Tags: Biotechnology / PharmaceuticalsHealthcare Services

Biotech Hits Critical Milestone for Cell-Pouch Bio-Hybrid Organ

  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) announces that the FDA has cleared its investigational new drug (IND) application for its cell pouch with auto-transplanted thyroid cells in patients undergoing thyroid surgery for nodular thyroid disease. Find out why one analyst sees big returns coming from the stock.
Tags: Biotechnology / Pharmaceuticals

Breakthrough ADHD Treatment Moves Closer to FDA Approval with New Data

  ()
Cingulate Inc.'s (CING:NASDAQ), latest Phase 3 data reinforces CTx-1301s potential as a true once-daily ADHD treatment. With an FDA meeting on the horizon, all eyes are on what's next.
Tags: Biotechnology / Pharmaceuticals

DMT Study Set To Explore Breakthrough Potential in Stroke Recovery

  ()
Algernon Pharmaceuticals Inc. (AGN:CSE; AGNPF:OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.
Tags: Biotechnology / Pharmaceuticals

Healthcare Pioneer Expands Revolutionary Treatment Platform

  ()
Leading regenerative medicine company Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) says it has submitted an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for its Cell Pouch technology. One analyst says it is the "most advanced encapsulation device in development."
Tags: Biotechnology / PharmaceuticalsMedical Devices

Biotherapeutic Co. Offers Potential Curative Alternative For Thyroid Disease

Research Report
  ()
Sernova Biotherapeutics Inc. (SVA:TSX.V; SEOVF:OTCQB; PSH:XETRA) recently filed a new IND for Cell Pouch in thyroid disease. Read on to see what rating and target price Leede Financial Inc. gave this company.
Tags: Biotechnology / Pharmaceuticals

Washington D.C. Pharma Co. Receives FDA Acceptance

Research Report
  ()
Vanda Pharmaceuticals Inc. (VNDA:NASDAQ) recently received FDA acceptance of its request for a hearing regarding its tradipitant New Drug Application, reported an H.C. Wainwright & Co. analyst.
Tags: Biotechnology / Pharmaceuticals

Biotech's Target Price 183.757% Higher Than Current

Research Report
  ()
Read on to see why D. Boral Capital analyst Jason Kolbert gave IMUNON Inc. (IMNM:NASDAQ) a high target price.
Tags: Biotechnology / Pharmaceuticals

AI Infrastructure Push: US$500 Billion Investment Accelerates Drug Discovery

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) highlights the transformative potential of the US$500 billion Stargate Initiative, set to revolutionize AI-driven drug discovery. Learn how this landmark investment could redefine oncology breakthroughs.
Tags: TechnologyBiotechnology / Pharmaceuticals

Biopharma Shares Multiple 2025 Catalysts

Research Report
  ()
Innate Pharma SA's (IPHA:NASDAQ; IPH:Paris) long-term corporate strategy led to it recieving a Buy rating from H.C. Wainwright & Co.
Tags: Biotechnology / Pharmaceuticals

Advanced AI Solutions Deliver Hope for CNS Cancer Treatment

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has identified AI-designed drug candidates targeting advanced cancer treatments with CNS penetration. Read more about how this breakthrough could redefine oncology innovation.
Tags: Biotechnology / Pharmaceuticals

Biotech Advances Breakthrough Cancer Treatment Results

Research Report
  ()
Sensei Biotherapeutics Inc. (SNSE:NASDAQ) is "well-positioned" to provide a clinical update on its drug targeting advanced solid tumors, Solnerstotug, in 2Q 2025, Oppenehimer & Co. Analyst Francois Brisebois writes in an updated research note.
Tags: Biotechnology / Pharmaceuticals

Pharma Innovator Reveals Groundbreaking Diabetes Treatment

Research Report
  ()
Biomea Fusion Inc.'s (BMEA:NASDAQ) drug could capture a significant share of the diabetes market, given the large target population globally, D. Boral Capital Analyst Jason Kolbert writes in an updated research note. Read why his target price is nearly a nearly 3,000% increase per share.
Tags: Biotechnology / Pharmaceuticals

AI-Driven Discovery Unveils Cancer Therapy Breakthrough, Exceeding Projections

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) has synthesized groundbreaking AI-designed drug candidates targeting critical cancer treatments. Discover how these innovations could reshape oncology research.
Tags: Biotechnology / Pharmaceuticals

Revenue Surge and Breakthrough Margins Fuel Growth in Critical Care Tech

  ()
CytoSorbents Corp. (CTSO:NASDAQ) reported a 22%-25% revenue jump in Q4, driven by strong performance and expanding global adoption of its flagship product. Read how regulatory breakthroughs in 2025 could redefine the company's market presence.
Tags: Biotechnology / Pharmaceuticals

Drug Innovator Launches Pivotal Cancer Trial Breakthrough

Research Report
  ()
Corvus Pharmaceuticals, Inc. (CRVS:NASDAQ) has the potential to generate hundreds of millions of dollars over the next decade with its drug candidates, an H.C. Wainwright & Co. analyst wrote in a January 2 research note.
Tags: Biotechnology / Pharmaceuticals

Pharma Innovator Unlocks Multi-Disease Treatment Potential

Research Report
  ()
Quince Therapeutics Inc. is "positioned for a transformative year" in 2025 with a solid cash position of US$47.8 million as of the third quarter of 2024. Find out why one analyst gives the stock a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Miami Biopharma Sells Part of Business and Begins New Clinical Trial

Research Report
  ()
Miami biopharmaceutical company Veru Inc. (VERU:NASDAQ) recently sold its FC2 Female Condom business for US$18 million, and has begun enrolling patients for its The Phase 2b QUALITY trial of enobosarm in combination with Wegovy (semaglutide) for sarcopenic obesity. Read on to see why one analyst gives this company a Buy rating.
Tags: Biotechnology / Pharmaceuticals

Analyst Initiates Coverage of Co. With 'Once-in-a-Generation' Drug

Research Report
  ()
NewAmsterdam Pharma Company N.V.'s (NAMS:NASDAQ) drug obicetrapib is a "once-in-a-generation" drug for cardiovascular disease, an analyst wrote in a research note while initiating coverage on the company. See what rating the stock got and its price per share target.
Tags: Biotechnology / Pharmaceuticals

Showing Results: 1 to 25 of 58 Next